01890nam a2200217Ia 4500003001000000005001700010040000900027245008300036490004700119520116200166650001301328650002001341650001701361650001701378650002901395650001601424700001901440700001601459856015601475008004101631MX-MdCICY20260521091351.0  cCICY10aLeishmaniasis: focus on the design of nanoparticulate vaccine delivery systems0 vExpert Rev. Vaccines, 11(1), p.69-86, 20123 aAlthough mass vaccination of the entire population of an endemic area would be the most cost-effective tool to diminish Leishmania burden, an effective vaccine is not yet commercially available. Practically, vaccines have failed to achieve the required level of protection, possibly owing to the lack of an appropriate adjuvant and/or delivery system. Therefore, there is still an imperative demand for an improved, safe and efficient delivery system to enhance the immunogenicity of available vaccine candidates. Nanoparticles are proficient in boosting the quality and magnitude of immune responses in a predictable fashion. Herein, we discuss how nanoparticulate vaccine delivery systems can be used to induce appropriate immune responses against leishmaniasis by controlling physicochemical properties of the vaccine. Stability, production reproducibility, low cost per dose and low risk-benefit ratios are desirable characteristics of an ideal vaccine formulation and solid lipid nanoparticles may serve as one of the most promising practical strategies to help to achieve such a leishmanial vaccine, at least in canine species in the developing world.14aADJUVANT14aDELIVERY SYSTEM14aLEISHMANIASI14aNANOPARTICLE14aSOLID LIPID NANOPARTICLE14aVACCINATION12aDelaram Doroud12aSima Rafati40uhttps://drive.google.com/file/d/1v2FvoTybDkbWwudbbk4hJj5V_YvrQVF3/view?usp=drivesdkzPara ver el documento ingresa a Google con tu cuenta: @cicy.edu.mx250602s9999    xx |||||s2   |||| ||und|d